SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 51.95 Billion KRW | 0.24% |
| 2022 | 51.83 Billion KRW | -5.59% |
| 2021 | 54.9 Billion KRW | 13.74% |
| 2020 | 48.26 Billion KRW | 8.31% |
| 2019 | 44.56 Billion KRW | -4.12% |
| 2018 | 46.48 Billion KRW | 10.89% |
| 2017 | 41.91 Billion KRW | -13.07% |
| 2016 | 48.22 Billion KRW | 14.37% |
| 2015 | 42.16 Billion KRW | 39.21% |
| 2014 | 30.28 Billion KRW | -35.45% |
| 2013 | 46.92 Billion KRW | -0.77% |
| 2012 | 47.28 Billion KRW | 7.28% |
| 2011 | 44.07 Billion KRW | 12.32% |
| 2010 | 39.24 Billion KRW | 5.9% |
| 2009 | 37.05 Billion KRW | 11.5% |
| 2008 | 33.23 Billion KRW | 1.32% |
| 2007 | 32.8 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 12.16 Billion KRW | 1.24% |
| 2024 Q2 | 10.57 Billion KRW | -13.07% |
| 2023 Q3 | 11.71 Billion KRW | -21.77% |
| 2023 Q4 | 12.02 Billion KRW | 2.58% |
| 2023 Q1 | 13.23 Billion KRW | -6.22% |
| 2023 FY | 51.95 Billion KRW | 0.24% |
| 2023 Q2 | 14.97 Billion KRW | 13.15% |
| 2022 FY | 51.83 Billion KRW | -5.59% |
| 2022 Q1 | 12.58 Billion KRW | -10.35% |
| 2022 Q2 | 11.23 Billion KRW | -10.74% |
| 2022 Q3 | 13.9 Billion KRW | 23.79% |
| 2022 Q4 | 14.11 Billion KRW | 1.53% |
| 2021 Q3 | 10.44 Billion KRW | -37.82% |
| 2021 Q1 | 13.6 Billion KRW | 123.3% |
| 2021 FY | 54.9 Billion KRW | 13.74% |
| 2021 Q2 | 16.8 Billion KRW | 23.49% |
| 2021 Q4 | 14.03 Billion KRW | 34.31% |
| 2020 Q2 | 12.14 Billion KRW | -9.7% |
| 2020 Q4 | 6.09 Billion KRW | -63.25% |
| 2020 FY | 48.26 Billion KRW | 8.31% |
| 2020 Q1 | 13.44 Billion KRW | 0.0% |
| 2020 Q3 | 16.58 Billion KRW | 36.57% |
| 2019 Q2 | 11.64 Billion KRW | 16.19% |
| 2019 Q1 | 10.02 Billion KRW | -11.29% |
| 2019 FY | 44.56 Billion KRW | -4.12% |
| 2019 Q3 | 23.33 Billion KRW | 100.42% |
| 2018 Q4 | 11.29 Billion KRW | 7.81% |
| 2018 Q2 | 13.35 Billion KRW | 17.67% |
| 2018 FY | 46.48 Billion KRW | 10.89% |
| 2018 Q1 | 11.35 Billion KRW | 87.09% |
| 2018 Q3 | 10.47 Billion KRW | -21.55% |
| 2017 Q3 | 10.92 Billion KRW | -11.48% |
| 2017 Q2 | 12.34 Billion KRW | -1.89% |
| 2017 Q1 | 12.58 Billion KRW | 0.27% |
| 2017 FY | 41.91 Billion KRW | -13.07% |
| 2017 Q4 | 6.06 Billion KRW | -44.48% |
| 2016 Q4 | 12.54 Billion KRW | -1.65% |
| 2016 FY | 48.22 Billion KRW | 14.37% |
| 2016 Q3 | 12.75 Billion KRW | 20.9% |
| 2016 Q2 | 10.55 Billion KRW | -14.63% |
| 2016 Q1 | 12.36 Billion KRW | -14.13% |
| 2015 Q1 | 7.09 Billion KRW | -6.65% |
| 2015 Q2 | 9.3 Billion KRW | 31.13% |
| 2015 Q3 | 9.79 Billion KRW | 5.26% |
| 2015 Q4 | 14.39 Billion KRW | 47.06% |
| 2015 FY | 42.16 Billion KRW | 39.21% |
| 2014 Q4 | 7.59 Billion KRW | 42.47% |
| 2014 Q3 | 5.33 Billion KRW | -42.14% |
| 2014 Q2 | 9.21 Billion KRW | 13.25% |
| 2014 Q1 | 8.13 Billion KRW | -9.85% |
| 2014 FY | 30.28 Billion KRW | -35.45% |
| 2013 Q2 | 14.46 Billion KRW | 15.26% |
| 2013 Q3 | 10.87 Billion KRW | -24.85% |
| 2013 Q4 | 9.02 Billion KRW | -16.96% |
| 2013 Q1 | 12.55 Billion KRW | -5.89% |
| 2013 FY | 46.92 Billion KRW | -0.77% |
| 2012 Q2 | 12.78 Billion KRW | 39.59% |
| 2012 Q1 | 9.16 Billion KRW | -11.07% |
| 2012 Q3 | 11.99 Billion KRW | -6.16% |
| 2012 Q4 | 13.33 Billion KRW | 11.15% |
| 2012 FY | 47.28 Billion KRW | 7.28% |
| 2011 FY | 44.07 Billion KRW | 12.32% |
| 2011 Q3 | 10.43 Billion KRW | -15.38% |
| 2011 Q4 | 10.3 Billion KRW | -1.24% |
| 2011 Q1 | 11.02 Billion KRW | 27.04% |
| 2011 Q2 | 12.32 Billion KRW | 11.83% |
| 2010 Q3 | 9.97 Billion KRW | -10.89% |
| 2010 FY | 39.24 Billion KRW | 5.9% |
| 2010 Q2 | 11.19 Billion KRW | 19.09% |
| 2010 Q1 | 9.39 Billion KRW | -4.32% |
| 2010 Q4 | 8.67 Billion KRW | -13.03% |
| 2009 Q2 | 8.84 Billion KRW | -8.26% |
| 2009 Q3 | 8.75 Billion KRW | -1.0% |
| 2009 Q1 | 9.63 Billion KRW | 4.75% |
| 2009 FY | 37.05 Billion KRW | 11.5% |
| 2009 Q4 | 9.82 Billion KRW | 12.23% |
| 2008 Q1 | 7.56 Billion KRW | -14.99% |
| 2008 Q2 | 7.99 Billion KRW | 5.79% |
| 2008 FY | 33.23 Billion KRW | 1.32% |
| 2008 Q3 | 8.47 Billion KRW | 5.94% |
| 2008 Q4 | 9.2 Billion KRW | 8.57% |
| 2007 Q3 | 7.96 Billion KRW | -2.05% |
| 2007 Q2 | 8.13 Billion KRW | 4.25% |
| 2007 Q4 | 8.89 Billion KRW | 11.61% |
| 2007 FY | 32.8 Billion KRW | 0.0% |
| 2007 Q1 | 7.8 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 62.135% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 95.41% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 91.862% |
| HANDOK Inc. | 522.74 Billion KRW | 90.061% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | 61.621% |
| Yuhan Corporation | 1858.98 Billion KRW | 97.205% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 92.175% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 96.515% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | 61.489% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 85.978% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | 41.356% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 69.36% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 76.853% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 62.135% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | 33.436% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 65.609% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | 40.53% |
| JW Holdings Corporation | 928.07 Billion KRW | 94.402% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 91.352% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 96.888% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 93.059% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 74.052% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 71.258% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 73.539% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 92.848% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 62.135% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 96.569% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 96.222% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 93.059% |
| Yuhan Corporation | 1858.98 Billion KRW | 97.205% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 93.462% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 77.882% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 91.262% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 93.059% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 82.215% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 81.374% |
| CKD Bio Corp. | 160.35 Billion KRW | 67.6% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 90.14% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 85.612% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 77.449% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 74.052% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 94.095% |
| Boryung Corporation | 859.62 Billion KRW | 93.956% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | 58.742% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 85.978% |
| JW Lifescience Corporation | 206.86 Billion KRW | 74.884% |